BRPI0412439A - compostos e composições compreendendo esteróis e/ou estanóis e inibidores de biossìntese de colesterol e uso dos mesmos no tratamento ou prevenção de uma variedade de doenças e condições - Google Patents

compostos e composições compreendendo esteróis e/ou estanóis e inibidores de biossìntese de colesterol e uso dos mesmos no tratamento ou prevenção de uma variedade de doenças e condições

Info

Publication number
BRPI0412439A
BRPI0412439A BRPI0412439-1A BRPI0412439A BRPI0412439A BR PI0412439 A BRPI0412439 A BR PI0412439A BR PI0412439 A BRPI0412439 A BR PI0412439A BR PI0412439 A BRPI0412439 A BR PI0412439A
Authority
BR
Brazil
Prior art keywords
compounds
compositions
diseases
variety
conditions
Prior art date
Application number
BRPI0412439-1A
Other languages
English (en)
Inventor
James P Kutney
Haydn P Pritchard
Tatjana Lukic
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Publication of BRPI0412439A publication Critical patent/BRPI0412439A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTOS E COMPOSIçõES COMPREENDENDO ESTERóIS E/OU ESTANóIS E INIBIDORES DE BIOSSìNTESE DE COLESTEROL E USO DOS MESMOS NO TRATAMENTO OU PREVENçãO DE UMA VARIEDADE DE DOENçAS E CONDIçõES". A presente invenção provê, em um aspecto, novos compostos compreendendo esteróis e/ou estanóis e inibidores de biossíntese de colesterol, incluindo sais destes compostos e solvatos e prodrogas destes compostos e/ou sais. Em outro aspecto, a presente invenção provê composições compreendendo pelo menos um éster esterol e/ou estanol e pelo menos um inibidor de síntese de colesterol. São também fornecidos métodos de tratamento ou prevenção de uma variedade de doenças, condições e distúrbios pela administração dos compostos ou composições fornecidas aqui.
BRPI0412439-1A 2003-07-09 2004-07-09 compostos e composições compreendendo esteróis e/ou estanóis e inibidores de biossìntese de colesterol e uso dos mesmos no tratamento ou prevenção de uma variedade de doenças e condições BRPI0412439A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61545603A 2003-07-09 2003-07-09
PCT/CA2004/000999 WO2005005453A2 (en) 2003-07-09 2004-07-09 Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.

Publications (1)

Publication Number Publication Date
BRPI0412439A true BRPI0412439A (pt) 2006-09-05

Family

ID=34062381

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412439-1A BRPI0412439A (pt) 2003-07-09 2004-07-09 compostos e composições compreendendo esteróis e/ou estanóis e inibidores de biossìntese de colesterol e uso dos mesmos no tratamento ou prevenção de uma variedade de doenças e condições

Country Status (13)

Country Link
EP (1) EP1644399A2 (pt)
JP (1) JP2007525470A (pt)
KR (1) KR20060052792A (pt)
CN (1) CN1832957A (pt)
AU (1) AU2004255285A1 (pt)
BR (1) BRPI0412439A (pt)
CA (1) CA2531836A1 (pt)
MX (1) MXPA06000326A (pt)
NO (1) NO20060632L (pt)
NZ (1) NZ545087A (pt)
PL (1) PL379516A1 (pt)
RU (1) RU2006103797A (pt)
WO (1) WO2005005453A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
WO2008032980A1 (en) * 2006-09-12 2008-03-20 Cns Pharm Korea Co., Ltd. Novel stigmasterol derivative or pharmaceutically acceptable salt thereof, method of producing the same, and composition containing the same to inhibit obesity or to prevent and treat hyperlipidemia
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6262723B2 (ja) * 2012-05-07 2018-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ オキシステロールアナログｏｘｙ１３３は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する
KR20140081339A (ko) * 2012-12-21 2014-07-01 부경대학교 산학협력단 푸코스테롤을 유효성분으로 포함하는 퇴행성 신경질환 예방 또는 치료용 약제학적 조성물
CA2911205A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
EP3617217B1 (en) 2014-12-09 2022-09-07 Warsaw Orthopedic, Inc. Process for the production of oxysterols
CN104434927A (zh) * 2014-12-16 2015-03-25 吉林农业大学 丙二酸双环戊烷并多氢菲酯b在制备降血压药物中的应用
US9987289B2 (en) 2015-07-10 2018-06-05 Warsaw Orthopedic, Inc. Slow release oxysterols and methods of use
US10632230B2 (en) 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
US9877836B2 (en) 2015-07-10 2018-01-30 Warsaw Orthopedic, Inc. Compression resistant implants including an oxysterol and methods of use
CN105055404B (zh) * 2015-08-19 2017-07-18 四川大学 Hmgcs2抑制剂在制备治疗***成瘾的药物中的用途
CN105087609B (zh) * 2015-08-19 2018-10-23 四川大学 一种重组慢病毒及其在制备治疗***成瘾的药物中的用途
US10688222B2 (en) 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
US11384114B2 (en) 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
US10434106B2 (en) * 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
KR102139994B1 (ko) * 2017-10-25 2020-07-31 대구대학교 산학협력단 스티그마스테롤을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물
CN113143935B (zh) * 2021-02-01 2022-10-11 广东药科大学 豆甾醇在制备改善心肌肥厚的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216015A (en) * 1991-02-05 1993-06-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having hypocholesterolemic properties
RU2002101483A (ru) * 1999-06-23 2003-09-20 Форбз Меди-Тек Инк. (Ca) Коньюгаты фитостерола или фитостанола с аскорбиновой кислотой и их применение для лечения или профилактики сердечно-сосудистых заболеваний

Also Published As

Publication number Publication date
MXPA06000326A (es) 2006-03-30
KR20060052792A (ko) 2006-05-19
WO2005005453A2 (en) 2005-01-20
EP1644399A2 (en) 2006-04-12
JP2007525470A (ja) 2007-09-06
AU2004255285A1 (en) 2005-01-20
NO20060632L (no) 2006-04-06
WO2005005453A3 (en) 2005-06-09
CN1832957A (zh) 2006-09-13
RU2006103797A (ru) 2006-07-27
PL379516A1 (pl) 2006-10-02
NZ545087A (en) 2009-10-30
CA2531836A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
BRPI0412439A (pt) compostos e composições compreendendo esteróis e/ou estanóis e inibidores de biossìntese de colesterol e uso dos mesmos no tratamento ou prevenção de uma variedade de doenças e condições
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
HUP0303929A2 (hu) Szubsztituált azetidinon vegyületeket tartalmazó gyógyszerkészítmények alkalmazása szitoszterinémia kezelésére
NO20050016L (no) Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen
BR9916565A (pt) Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
BR9916567A (pt) Combinações de inibidores do transporte ácido dabile ileal e derivados do ácido nicotìnico paraindicações cardiovasculares
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
MX2009005201A (es) Derivados de estratrieno sustituidos como inhibidores de 17beta hsd.
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
TW200509937A (en) Novel compounds and their use in therapy
WO2005077968A3 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
MXPA05009535A (es) Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos.
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
MX2007006279A (es) Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa.
MXPA02010316A (es) Terapia novedosa para los trastornos asociados con la hiperlipidemia.
MXPA04008303A (es) Inhibidores de la farnesil proteina transferasa como agentes antitumorales.
MX2007003158A (es) Forma cristalina 2 del clorhidrato de atrasentan.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A,6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.